A window of opportunity for no treatment in early multiple sclerosis?

被引：9
作者：
Gilmore, C. P. [6 ]
Cottrell, D. A. [5 ]
Scolding, N. J. [4 ]
Wingerchuk, D. M. [3 ]
Weinshenker, B. G. [2 ]
Boggild, M. [1 ]
机构：
[1] Walton Ctr Neurol & Neurosurg, Liverpool L9 7LJ, Merseyside, England
[2] Mayo Clin, Dept Neurol, Rochester, MN USA
[3] Mayo Clin, Dept Neurol, Scottsdale, AZ USA
[4] Univ Bristol, Frenchay Hosp, Inst Clin Neurosci, Bristol, Avon, England
[5] Frenchay Hosp, Dept Neurol, Bristol BS16 1LE, Avon, England
[6] Nottingham Univ Hosp NHS Trust, Dept Neurol, Nottingham, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2010年 / 16卷 / 06期
关键词：
INTERFERON BETA-1B; DOUBLE-BLIND; FOLLOW-UP; DISABILITY; DEFINITE; MRI; MULTICENTER; CONVERSION; BRAIN; EVENT;
D O I：
10.1177/1352458510366014
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：756 / 759
页数：4
相关论文
共 24 条
  • [1] [Anonymous], ADV CLIN NEUROSCI RE
  • [2] Axonal loss in normal-appearing white matter in a patient with acute MS
    Bjartmar, C
    Kinkel, RP
    Kidd, G
    Rudick, RA
    Trapp, BD
    [J]. NEUROLOGY, 2001, 57 (07) : 1248 - 1252
  • [3] Brodsky M, 2008, ARCH NEUROL-CHICAGO, V65, P727, DOI 10.1001/archneur.65.6.727
  • [4] Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
    Comi, G.
    Martinelli, V.
    Rodegher, M.
    Moiola, L.
    Bajenaru, O.
    Carra, A.
    Elovaara, I.
    Fazekas, F.
    Hartung, H. P.
    Hillert, J.
    King, J.
    Komoly, S.
    Lubetzki, C.
    Montalban, X.
    Myhr, K. M.
    Ravnborg, M.
    Rieckmann, P.
    Wynn, D.
    Young, C.
    Filippi, M.
    [J]. LANCET, 2009, 374 (9700) : 1503 - 1511
  • [5] Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study
    Comi, G
    Filippi, M
    Barkhof, F
    Durelli, L
    Edan, G
    Fernández, O
    Hartung, HP
    Seeldrayers, P
    Sorensen, PS
    Rovaris, M
    Martinelli, V
    Hommes, OR
    [J]. LANCET, 2001, 357 (9268) : 1576 - 1582
  • [6] MRI as an outcome in multiple sclerosis clinical trials
    Daumer, M.
    Neuhaus, A.
    Morrissey, S.
    Hintzen, R.
    Ebers, G. C.
    [J]. NEUROLOGY, 2009, 72 (08) : 705 - 711
  • [7] Disability as an outcome in MS clinical trials
    Ebers, G. C.
    Heigenhauser, L.
    Daumer, M.
    Lederer, C.
    Noseworthy, J. H.
    [J]. NEUROLOGY, 2008, 71 (09) : 624 - 631
  • [8] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    Ebers, GC
    Rice, G
    Lesaux, J
    Paty, D
    Oger, J
    Li, DKB
    Beall, S
    Devonshire, V
    Hashimoto, S
    Hooge, J
    Kastrukoff, L
    Krieger, C
    Mezei, M
    Seland, P
    Vorobeychi, G
    Morrison, W
    Nelson, J
    Freedman, MS
    Chrisie, S
    Nelson, R
    Rabinovitch, H
    Freedman, C
    Hartung, HP
    Rieckmann, P
    Archelos, J
    Jung, S
    Weilbach, F
    Flachenecke, P
    Sauer, J
    Hommes, O
    Jongen, P
    Brouwer, S
    McLeod, J
    Pollard, J
    Ng, R
    Sandberg-Wollheim, M
    Källén, K
    Nilsson, P
    Ekberg, R
    Lundgren, A
    Jadbäck, G
    Wikström, J
    Multanen, J
    Valjakka, M
    Carton, H
    Lissoir, F
    Declerq, I
    Vieren, M
    Peeters, E
    Dubois, B
    [J]. LANCET, 1998, 352 (9139) : 1498 - 1504
  • [9] Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
    Filippi, M
    Rovaris, M
    Inglese, M
    Barkhof, F
    De Stefano, N
    Smith, S
    Comi, G
    [J]. LANCET, 2004, 364 (9444) : 1489 - 1496
  • [10] Disability and T2 MRI lesions:: a 20-year follow-up of patients with relapse onset of multiple sclerosis
    Fisniku, L. K.
    Brex, P. A.
    Altmann, D. R.
    Miszkiel, K. A.
    Benton, C. E.
    Lanyon, R.
    Thompson, A. J.
    Miller, D. H.
    [J]. BRAIN, 2008, 131 : 808 - 817
123